

A full list of abstract titles and viewing details are listed below:

| Abstract Title | Author | Presentation Type/# | Session Title | Presentation Date/Time (CST) |
|--|-------------------------|------------------------------|--|---|
| Inluriyo (imlunestrant) | | | | |
| Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial | Komal Jhaveri | Oral Presentation #GS3-08 | General Session 3 | Friday, December 12 10:45-11:00 a.m. CST |
| Real-world ESR1 mutation (ESR1m) testing and positivity rates in patients with ER+/HER2- metastatic breast cancer (MBC) | Lindsay Williams | Poster #PS1-12-08 | Poster Session 1 | Wednesday, December 10 12:30-2:00 p.m. CST |
| Patient Experience with Intramuscular vs. Oral Endocrine Therapy in Metastatic Breast Cancer | Erica Fortune | Poster #PS1-03-03 | Poster Session 1 | Wednesday, December 10 12:30-2:00 p.m. CST |
| Circulating Tumour DNA (ctDNA) Dynamics From Patients With ER+, HER2- Advanced Breast Cancer in the Phase 3 EMBER-3 Trial | Francois Clement Bidard | Poster #PD5-08 | Poster Spotlight 5: Liquid Biomarkers in Breast Cancer- Driving Precision Medicine | Thursday, December 11 8:03-8:06 a.m. CST |
| Verzenio® (abemaciclib) | | | | |
| MonarchE: subgroup analysis of adjuvant abemaciclib + endocrine therapy for HR+, HER2-, high-risk early breast cancer by nodal status | Javier Cortes | Poster #PS1-08-08 | Poster Session 1 | Wednesday, December 10, 2025 12:30-2:00 p.m. CST |
| Abemaciclib plus endocrine therapy in HR+/HER2- advanced breast cancer: insights from an Italian retrospective observational study | Elisabetta Munzone | Poster #PS5-04-08 | Poster Session 5 | Friday, December 12 12:30-2:00 p.m. CST |
| Treatment Persistence and Dosing Patterns in US Patients with HR+/HER2-, Node-Positive Early Breast Cancer Treated with Adjuvant Abemaciclib | Hatem Soliman | Poster #PS5-05-09 | Poster Session 5 | Friday, December 12 12:30-2:00 p.m. CST |
| LY4064809 (STX-478) | | | | |
| A phase 1/2 trial of LY4064809 (STX-478), a pan-mutant-selective PI3Kα inhibitor in HR+, HER2- advanced breast cancer (ABC), Updated results from PIKALO-1 | Komal Jhaveri | Poster #PS1-08-24 | Poster Session 1 | Wednesday, December 10, 2025 12:30-2:00 p.m. CST |